Drug-eluting versus bare-metal stents in large coronary arteries

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomaterials Science

Background:

• First-generation drug-eluting stents (DES) were linked to increased late cardiac events in large coronary arteries.
• Second-generation DES aim to improve safety and efficacy profiles.
• Assessing the comparative safety and effectiveness of second-generation DES versus bare-metal stents (BMS) is crucial.

Purpose of the Study:

• To confirm if first-generation DES pose a higher risk for late cardiac events.
• To evaluate if second-generation DES also present an increased risk compared to BMS.
• To compare the rates of death, myocardial infarction, and target-vessel revascularization between different stent types.

Main Methods:

• A randomized trial involving 2314 patients with large coronary arteries (≥3.0 mm diameter).
• Patients received sirolimus-eluting stents, everolimus-eluting stents, or bare-metal stents.
• Primary endpoint: composite of cardiac death or nonfatal myocardial infarction at 2 years. Secondary endpoints: late events and target-vessel revascularization.

Main Results:

• No significant differences in the primary endpoint (cardiac death/myocardial infarction) between DES and BMS groups.
• Similar rates of late events, death, myocardial infarction, and stent thrombosis across all stent types.
• Significantly lower target-vessel revascularization rates observed with both sirolimus-eluting and everolimus-eluting stents compared to BMS.

Conclusions:

• Second-generation DES (sirolimus-eluting and everolimus-eluting) are not associated with increased rates of death or myocardial infarction in large coronary arteries.
• Both second-generation DES demonstrated comparable and significant reductions in target-vessel revascularization versus BMS.
• These findings support the use of second-generation DES for improved revascularization outcomes without compromising safety.